GlobeNewswire Inc.··NaAktis Oncology Advances Radioconjugate Pipeline With First AKY-2519 Clinical Data
Aktis Oncology presents inaugural clinical data for AKY-2519 radioconjugate at ASCO 2026, with Phase 1b trial launching mid-year following FDA IND clearance.
AKTSsolid tumorsFDA clearance